BioVision 10/16

PRODUCT: PFI-2

ALTERNATE NAME: (R)-8-fluoro-N-(1-oxo-1-(pyrrolidin-1-yl)-3-(3-

(trifluoromethyl)phenyl)propan-2-yl)-1,2,3,4-

tetrahydroisoquinoline-6-sulfonamide

CATALOG #: B1259-5,25

AMOUNT: 5 mg, 25 mg

STRUCTURE:

MOLECULAR FORMULA: C₂₃H₂₅F₄N₃O₃S

MOLECULAR WEIGHT: 499.52

CAS NUMBER: 1627676-59-8

APPEARANCE: Crystalline solid

SOLUBILITY: DMSO (30 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: Store at -20°C. Protect from air and light.

DESCRIPTION: PFI-2 is a novel potent and selective SETD7 histone lysine

methyltransferase inhibitor (IC_{50} ~2 nM). It has > 100-fold selectivity over other methyltransferases and other non-epigenetic targets. PFI-2 has been shown to bind to SETD7 by ITC (Kd = 18 nM), and biotinylated PFI-2 interacts with

SETD7 in pull-down studies.

REFERENCES: Li, F., et al. (2014). Proc. Natl. Acad. Sci. USA 111, 12853

HANDLING: Do not take internally. Wear gloves and mask when handling

the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

AS8351 (Cat. No. B1082-5,25)

Caffeic acid (Cat. No. 2303-50, 250)

Clorgyline hydrochloride (Cat. No. 2622-10, 50)

Daminozide (Cat. No. 2438-100, 500)

Disulfiram (Cat. No. 2308-10, 50)

Ebselen (Cat. No. 2169-5, 25)

GSK-J4 hydrochloride (Cat. No. 2259-1, 5)

GSK-J4 (Free base) (Cat. No. 2762-1,5)

GSK-J1 sodium (Cat. No. 2260-1, 5)

GSK-J1 (Cat. No. 2761-1,5)

GSK-LSD1 hydrochloride (Cat. No. B1258-5,25)

Harmine (Cat. No. 2561-50, 250)

IOX1 (Cat. No. 2266-5, 25)

Jumonji HDM Inhibitor, JOB-04 (Cat. No. 2474-5, 25)

Jumonji HDM Inhibitor, PBIT (Cat. No. 2475-5, 25)

β-Lapachone (Cat. No. 2262-5, 25)

ML-324 (Cat. No. 2763-5, 25)

OG-L002 (Cat. No. 9406-5, 25)

Pargyline hydrochloride (Cat. No. 2618-500, 1000)

2,4-PDCA (Cat. No. 2304-100, 500)

PFI-2 (Cat. No. B1259-5,25)

Rasagiline mesylate (Cat. No. 2237-50, 250)

SP-2509 (Cat. No. 9446-5,25)

Tranylcypromine hemisulfate (Cat. No. 1816-25, 100)

USAGE: FOR RESEARCH CH USE ONLY! Not to be used in humans